Prithviraj Bose, MD

Articles by Prithviraj Bose, MD

Optimizing Future Combination Approaches in Myelofibrosis

ByPrithviraj Bose, MD,Pankit Vachhani, MD

March 19th 2026

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how future

How Selinexor Plus Ruxolitinib Could Affect Frontline Myelofibrosis Management

ByPrithviraj Bose, MD,Pankit Vachhani, MD

March 12th 2026

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how selinexor plus ruxolitinib could affect the frontline myelofibrosis treatment paradigm.

Key Findings to Watch in SENTRY Trial of Selinexor/Ruxolitinib in Myelofibrosis

ByPrithviraj Bose, MD,Pankit Vachhani, MD

March 12th 2026

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the key objectives of the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor–naive myelofibrosis.

The SENTRY Trial: Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

ByPrithviraj Bose, MD,Pankit Vachhani, MD

March 5th 2026

Prithviraj Bose, MD, and Pankit Vachhani, MD, overview the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor–naive myelofibrosis

Background on the Investigation of Selinexor in Myelofibrosis

ByPrithviraj Bose, MD,Pankit Vachhani, MD

March 5th 2026

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the mechanism of action of selinexor and the rationale for investigating the agent in myelofibrosis.

When to Initiate Therapy in Myelofibrosis: The Role of Early Intervention

ByPrithviraj Bose, MD,Pankit Vachhani, MD

February 26th 2026

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the importance of early intervention and when to initiate treatment in myelofibrosis.

The Limitations of JAK Inhibitors in Myelofibrosis Management

ByPrithviraj Bose, MD,Pankit Vachhani, MD

February 26th 2026

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the limitations of currently approved JAK inhibitors in the treatment of myelofibrosis.

Prithviraj Bose, MD, and Chandler Park, MD, FACP

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

ByPrithviraj Bose, MD,Javier Pinilla, MD, PhD,Chandler Park, MD, MSc, FACP

December 8th 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Future of MF

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 16th 2024

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Combination Therapies for MF Management

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 9th 2024

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Future of PV: Unmet Needs

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 9th 2024

Faculty offer insights into the future of PV management as well as unmet needs.

Monitoring Patients on Myelofibrosis Treatment

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 2nd 2024

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Treating Patients with Myelofibrosis and Anemia

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 2nd 2024

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 26th 2024

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Role of Transplant in Myelofibrosis

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 26th 2024

Panel experts comment on the role of transplant in patients with myelofibrosis.

MAJIC-PV: Clinical Implications in PV

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Polycythemia Vera: Treatment Goals and Options

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 12th 2024

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

REVEAL Study: Clinical Implications

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 12th 2024

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Polycythemia Vera: Assessing Risk and Genetic Testing

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 12th 2024

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Diagnosing Polycythemia Vera (PV)

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

December 19th 2023

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

ByPankit Vachhani, MD,Prithviraj Bose, MD

September 26th 2023

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Prithviraj Bose, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Dr Bose on the Use of Zilurgisertib With/Without Ruxolitinib to Reduce Anemia in Myelofibrosis

ByPrithviraj Bose, MD

June 15th 2023

Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.

Dr Bose on Spleen and Symptom Benefit With Pacritinib in Myelofibrosis

ByPrithviraj Bose, MD

June 6th 2023

Prithviraj Bose, MD, discusses key data on the ability of pacritinib to reduce splenomegaly and disease symptoms in patients with myelofibrosis across the cytopenic spectrum.

Unmet Needs in SM Treatment

ByDaniel J. DeAngelo, MD, PhD,Prithviraj Bose, MD,Patricia Lugar, MD, MS, Duke Health,Sa Wang, MD, MD Anderson Cancer Center

September 27th 2021

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Chronic Myelomonocytic Cell Leukemia: Clinical Considerations

ByDaniel J. DeAngelo, MD, PhD,Prithviraj Bose, MD,Sa Wang, MD, MD Anderson Cancer Center

September 27th 2021

The panel of experts discuss the diagnosis and assessment of chronic myelomonocytic cell leukemia.

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

ByDaniel J. DeAngelo, MD, PhD,Sa Wang, MD,Patricia L. Lugar, MD, MS,Prithviraj Bose, MD

September 15th 2021

Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.